Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Li Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5348-3681; OpenAlex author ID A5057701440. Sources: OpenAlex.

Their work

Papers
50 (first author 8, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: 7 papers · 2015: 6 papers · 2016: 6 papers · 2017: 4 papers · 2018: 3 papers · 2019: 2 papers · 2020: 9 papers · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 2 papers

Papers 50

  1. Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Co-author DOI 10.1016/j.canlet.2024.217280↗
  2. MLH1 Inhibits Metastatic Potential of Pancreatic Ductal Adenocarcinoma via Downregulation of GPRC5C. Last author DOI 10.1016/j.labinv.2024.102107↗
  3. FGFR3 Nuclear Translocation Contributes to Proliferative Potential and Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002056↗
  4. Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer. First author DOI 10.1080/00365521.2020.1853806↗
  5. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic… Co-author DOI 10.1097/mpa.0000000000001892↗
  6. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients… First author DOI 10.1111/jgh.15244↗
  7. Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.812785↗
  8. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  9. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  10. Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going? Co-author DOI 10.1016/j.pdpdt.2020.101876↗
  11. Ubiquitin-specific protease 4 predicts an unfavorable prognosis and promotes malignant behaviors in vitro in pancreatic cancer. First author DOI 10.1016/j.yexcr.2020.112317↗
  12. Matrix Metalloproteinase 11 as a Novel Tumor Promoter and Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001583↗
  13. Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer. First author DOI 10.1186/s12935-020-01550-y↗
  14. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00576↗
  15. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Co-author DOI 10.3389/fonc.2020.01466↗
  16. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? First author DOI 10.3389/fonc.2020.576399↗
  17. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.humpath.2018.11.026↗
  18. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0777-7↗
  19. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.25253↗
  20. High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.prp.2017.11.013↗
  21. Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.4103/0366-6999.247211↗
  22. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗
  23. Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages. Co-author DOI 10.1016/j.cyto.2015.12.003↗
  24. Surgeons' knowledge regarding the diagnosis and management of pancreatic cancer in China: a cross-sectional study. Co-author DOI 10.1186/s12913-017-2345-6↗
  25. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.5784↗
  26. Expression and Significances of MTSS1 in Pancreatic Cancer. Co-author DOI 10.1007/s12253-015-9963-2↗
  27. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.humpath.2016.06.012↗
  28. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/s1001-9294(16)30043-8↗
  29. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Co-author DOI 10.1097/sla.0000000000001345↗
  30. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Co-author DOI 10.1186/s13046-016-0406-z↗
  31. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.11330↗
  32. Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1038/srep16067↗
  33. Catechol-O-methyltransferase, a new target for pancreatic cancer therapy. Co-author DOI 10.1111/cas.12648↗
  34. MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP. Co-author DOI 10.1371/journal.pone.0116934↗
  35. Cancer-associated fibroblasts in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon.15.176↗
  36. HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer. Co-author PMID 26692947↗
  37. Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. Co-author PMID 26823787↗
  38. N-wasp in pancreatic ductal adenocarcinoma: associations with perineural invasion and poor prognosis. Co-author DOI 10.1007/s00268-014-2500-8↗
  39. The prognostic value of Cyclin B1 in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0107-4↗
  40. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer. Co-author DOI 10.1016/j.arcmed.2013.10.001↗
  41. Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Co-author DOI 10.1016/s1499-3872(14)60272-1↗
  42. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Co-author DOI 10.18632/oncotarget.1890↗
  43. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Co-author DOI 10.18632/oncotarget.2184↗
  44. [Application of miRNAs in the occurrence and early diagnosis of pancreatic cancer]. Co-author PMID 24785459↗
  45. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer. Co-author DOI 10.1007/s00268-013-2010-0↗
  46. MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer. Co-author DOI 10.1007/s11605-013-2230-5↗
  47. Oligonucleotide microarray identifies genes differentially expressed during tumorigenesis of DMBA-induced pancreatic cancer in rats. Co-author DOI 10.1371/journal.pone.0082910↗
  48. Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters. Co-author DOI 10.1007/s11427-012-4375-y↗
  49. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Co-author DOI 10.1016/s1499-3872(12)60168-4↗
  50. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Co-author DOI 10.1016/j.arcmed.2011.01.006↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei You · 32 shared papers, 2012–2022 · strength 2.29
  2. Jun Lü · 17 shared papers, 2017–2024 · strength 2.15
  3. Junchao Guo · 23 shared papers, 2013–2024 · strength 2.13
  4. Zhiyong Liang · 17 shared papers, 2015–2022 · strength 1.57
  5. Bolun Jiang · 11 shared papers, 2020–2024 · strength 1.50
  6. Yu-Pei Zhao · 23 shared papers, 2011–2020 · strength 1.38
  7. Taiping Zhang · 23 shared papers, 2011–2020 · strength 1.32
  8. Yizhi Wang · 7 shared papers, 2020–2021 · strength 0.91
  9. Yupei Zhao · 14 shared papers, 2012–2020 · strength 0.87
  10. Jianzhou Liu · 3 shared papers, 2021–2024 · strength 0.59
  11. Quan Liao · 8 shared papers, 2015–2020 · strength 0.55
  12. Yizhi Wang · 4 shared papers, 2020–2022 · strength 0.51
  13. Wen-Jing Liu · 4 shared papers, 2013–2024 · strength 0.50
  14. Junchao Guo · 4 shared papers, 2016–2020 · strength 0.43
  15. Gary Guishan Xiao · 3 shared papers, 2020–2024 · strength 0.42
  16. Qiaofei Liu · 3 shared papers, 2017–2024 · strength 0.36
  17. Jianwei Xu · 6 shared papers, 2014–2019 · strength 0.32
  18. Bingqi Li · 4 shared papers, 2017–2019 · strength 0.32
  19. Zheyu Niu · 5 shared papers, 2015–2017 · strength 0.32
  20. Mengyi Wang · 5 shared papers, 2015–2017 · strength 0.32
  21. Hong Shu · 7 shared papers, 2012–2014 · strength 0.27
  22. Wenming Wu · 5 shared papers, 2012–2020 · strength 0.25
  23. Lutian Yao · 4 shared papers, 2015–2017 · strength 0.23
  24. Boju Pan · 3 shared papers, 2015–2020 · strength 0.21
  25. Tianxiao Wang · 5 shared papers, 2013–2016 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.